Infantile Epileptic Spasms Syndrome and Trisomy 21: Treatment response and outcomes

Glineur M², Toulas J¹, Vuillemin-Massie L¹, Camus M¹, Montagutelli D¹, Prioux E¹, Pernaudet M¹, Khau A¹, Maillard P-Y¹, Clert M¹, Martet D¹, Falquero S¹, Sanogo l¹, Caillaud M-A¹, Mircher C¹, Cieuta-Walti C¹² Sherbrooke University of Medicine, Sherbrooke Quebec, Canada

Introduction:

CONTEXT: In France, the current treatment protocol for infantile epileptic spasms syndrome (IESS) in Down Syndrome (DS) consists of a first line monotherapy with vigabatrin (VGB) and if failed, the addition of oral corticosteroids or less frequently bitherapy (combination of vigabatrin and prednisone) from the start.
OBJECTIVE: Our aim is to describe IESS cases followed at Institut Jérôme Lejeune, in terms of therapeutic response, side effects and evolution following received treatment protocols.

Methods:

Retrospective study based on the electronic medical files of DS children with the diagnosis of IESS followed up in a trisomy 21 expert medical center, Institut Jerome Lejeune between 2012 and 2023. Table 2 : Description of spasm characteristics and long term outcomes in VGB monotherapy vs. VGB and cortisone (bitherapy) groups, as first medication.

	First line therapy				
	VGB (N = 38)	VGB + Cortisone (N = 5)			
SF.* after 1st line drug	12/38 (32)	1/5 (20)			
Time between					
diagnosis and SF.	3 (1.0, 5.8)	3.5 (3.3, 3.8)			
(months)					
Missing data	11	3			
Spasms characteristics (months)					
Age at onset	6.0 (5.5, 9.3)	6.0 (5.5, 8.5)			
Missing data	6	2			
Age at diagnosis	8.6 (7.0, 13.3)	7.7 (7.2, 9.0)			
Time between onset					
and diagnosis	1.3 (0.6, 3.5)	1.2 (0.8, 1.2)			
Missing data	6	2			
Follow up period	80 (42, 121)	22 (17, 63)			
Age at last follow-up	87 (49, 134)	29 (23, 74)			
Number of drugs needed	to achieve spasi	ns cessation			
1	12/37 (32)	C			
2	6/37 (16)	1/5 (20)			
3	5/37 (14)	3/5 (60)			
4	8/37 (22)				
5	4/37 (11)	1/5 (20)			
6	2/37 (5.4)	C			
At last follow-up:					
Active epilepsy	8/38 (21)	C			
Long term treatment**	32/36 (89)	3/4 (75)			
ASD	10/37 (27)	1/5 (20)			
Severe developement					
delay	11/28 (39)	1/3 (33)			
Behavior concerns	11/37 (30)	C			
Lennox-Gastaut	3/37 (8.1)				

Results:

Diagram 1: Breakdown of different therapies in our cohort




Table 1 : Patients' demographic and clinical characteristics

	T21 with West Syndrome (N = 45)	T21 without West Syndrome (N = 366)*	
Female	12/45 (27)	167/366 (46)	
Genetic diagnosis			
T21 free and homogenous	31/45 (69)	366/366 (100)	
T21 clinical	9/45 (20)	0	
Other : translocation,			
mosaique, unkown,	5/45 (11)	0	
Comorbidities			
Cardiac	20/45 (44)	215/338 (64)	
Dysthyroidism	15/45 (33)	97/340 (29)	
Gastro-intestinal	4/45 (8.9)	68/241 (28)	
Prematurity	10/45 (22)	22/188 (12)	
Regression at presentation	30/38 (79)	N/A	
*Children between 6 and 8 years of age with T21 free and homogenous diagnosis without any history of spasms Statistics: n/N (%)			

	*SF = Seizure free
**Anti-epileptic drugs for more than 12 months	
	Statistics: n/N (%), for qualitative data
-	Median (Q1, Q3), for quantitative data

Table 3: Medication side effects in the two groups

	First line therapy	
	VGB (N = 38)	VGB + Cortisone (N = 5)
Side effects	16/37 (43)	2/5 (40)
Irritability	4/37 (11)	1/5 (20)
Sedation	9/37 (24)	1/5 (20)
Myoclonus	7/37 (19)	0
Encephalopathy	1/37 (2,7)	0
Hypertension	1/37 (2,7)	0
Weight gain	2/37 (5.4)	1/5 (20)
Severe infection	1/37 (2,7)	0
Death	1/37 (2,7)	0

Conclusion:

Discussion:

On the 45 DS children included, 38 (84%) received a first line monotherapy and 5 (11%) a bitherapy. Spasms stopped in 44 of them (97.8%). Only 12/38 (32%) receiving monotherapy were seizure free after one medication (VGB). Whereas in the bitherapy group, 1/5 (20%) were seizure free after their first line therapy (VGB + cortisone). The two groups had a similar percentage of side effects. At their last follow-up, 10/37 (27%) receiving monotherapy were diagnosed with autism spectrum disorder, 8/38 (21%) had active epilepsy and 11/28 (39%) severe developmental concerns. The results show a poor response to the current French treatment protocol for IESS in DS with an unfavorable outcome and highlight the importance of studying the pathophysiology of this syndrome in DS to establish a more targeted treatment.

<u>Dre Cécile CIEUTA-WALTI</u>, Neuropédiatre, professeure attachée à l'Université de Sherbrooke, Canada, Institut Jérôme Lejeune, Paris, cecile.cieuta-walti@institutlejeune.org <u>Margaux GLINEUR</u>, Externe étudiante aux études médicales prédoctorales, promotion 2025, Faculté de médecine et des sciences de la sancé, Université de Sherbrooke, margaux.glineur@usherbrooke.ca



www.institutlejeune.org





P167